Alan joined CellCentric in January 2025.

Alan is an experienced program director who has defined and implemented the program management and governance strategies for non-clinical and clinical development plans at several biotechs.

He has managed program teams and assets across a variety of indications and modalities. Most recently, he was at Abbvie through an acquisition of Immunogen in 2024.

Alan has an MS in bioengineering from Tufts University.